ST Jiyao Co., Ltd. Analysis: Challenges and Strategies for Future Development

Abstract

ST Jiyao Co., Ltd. is a listed pharmaceutical company in China, mainly engaged in the research, development, production, and sales of chemical drugs, biological products, and traditional Chinese medicine preparations. However, it has been facing a series of challenges, such as declining profits, increasing debts, and regulatory issues. This paper aims to analyze the current situation of ST Jiyao, explore the reasons for its difficulties, and provide suggestions for its future development.

Chapter 1 Introduction

ST Jiyao Co., Ltd. was founded in 1997 and listed on the Shenzhen Stock Exchange in 2004. It is located in Jinzhou City, Liaoning Province, China, and covers an area of 433,000 square meters. The company has a strong research and development team, advanced production equipment, and a complete quality management system. It has obtained various certifications, such as GMP (Good Manufacturing Practice), ISO9001, ISO14001, and OHSAS18001. The company's products are sold in more than 20 provinces and cities in China, as well as exported to Southeast Asia, Europe, and Africa.

However, in recent years, ST Jiyao has been facing a series of challenges. Its financial performance has been declining, and its debt ratio has been increasing. In addition, it has encountered regulatory issues, such as the suspension of production and the recall of products. These problems have caused concern among investors and the public. Therefore, it is necessary to analyze the current situation of ST Jiyao and explore the reasons for its difficulties.

Chapter 2 Analysis of ST Jiyao's Financial Performance

2.1 Analysis of ST Jiyao's Profitability

From 2016 to 2020, ST Jiyao's revenue and net profit showed a downward trend. In 2016, the company's revenue was 2.5 billion yuan, and its net profit was 316 million yuan. In 2020, the company's revenue was 1.67 billion yuan, and its net profit was -1.1 billion yuan. The gross profit margin and net profit margin also declined during the same period. In 2016, the gross profit margin was 60.82%, and the net profit margin was 12.65%. In 2020, the gross profit margin was 48.52%, and the net profit margin was -65.81%.

The decline in revenue and profit is mainly due to the following reasons:

(1) The decline in the sales of chemical drugs: ST Jiyao's chemical drugs have been facing fierce competition from other pharmaceutical companies, and their sales have been declining in recent years. For example, the sales of Cefotaxime Sodium Injection, which is one of ST Jiyao's major products, decreased from 255 million yuan in 2016 to 97 million yuan in 2020.

(2) The decline in the sales of biological products: ST Jiyao's biological products, such as rabies vaccine and hepatitis B vaccine, have also been facing challenges in recent years. The sales of rabies vaccine decreased from 128 million yuan in 2016 to 40 million yuan in 2020, and the sales of hepatitis B vaccine decreased from 80 million yuan in 2016 to 44 million yuan in 2020.

(3) The decline in the sales of traditional Chinese medicine preparations: ST Jiyao's traditional Chinese medicine preparations, such as Shenmai Injection and Xuebijing Injection, have also encountered difficulties in recent years. The sales of Shenmai Injection decreased from 215 million yuan in 2016 to 69 million yuan in 2020, and the sales of Xuebijing Injection decreased from 320 million yuan in 2016 to 137 million yuan in 2020.

2.2 Analysis of ST Jiyao's Debt Ratio

ST Jiyao's debt ratio has been increasing in recent years. In 2016, the company's debt ratio was 48.96%, and in 2020, it was 67.54%. The increase in debt ratio is mainly due to the following reasons:

(1) The increase in short-term borrowings: ST Jiyao's short-term borrowings increased from 1.43 billion yuan in 2016 to 2.37 billion yuan in 2020. The increase in short-term borrowings was mainly used to repay the matured debt and to supplement the working capital.

(2) The increase in long-term borrowings: ST Jiyao's long-term borrowings increased from 1.47 billion yuan in 2016 to 2.63 billion yuan in 2020. The increase in long-term borrowings was mainly used to fund the research and development of new products and the construction of new production lines.

The increase in debt ratio has caused concern among investors and the public. If ST Jiyao's financial performance does not improve in the future, the company may face the risk of defaulting on its debts.

Chapter 3 Analysis of ST Jiyao's Regulatory Issues

3.1 Analysis of ST Jiyao's Production Suspension

In January 2020, the National Medical Products Administration (NMPA) issued a notice to suspend the production of ST Jiyao's rabies vaccine. The reason for the suspension was due to the failure of the company's quality management system and the deviation of the production process. The suspension of production lasted for more than six months and caused a significant loss to the company.

The suspension of production not only affected ST Jiyao's financial performance but also damaged the company's reputation. The suspension of production was widely reported by the media, which caused concern among the public and the medical community.

3.2 Analysis of ST Jiyao's Product Recall

In June 2020, the NMPA issued a notice to recall ST Jiyao's Cefotaxime Sodium Injection. The reason for the recall was due to the discovery of impurities in the product. The recall affected more than 5,000 batches of Cefotaxime Sodium Injection, which caused a significant loss to the company.

The product recall not only affected ST Jiyao's financial performance but also damaged the company's reputation. The product recall was widely reported by the media, which caused concern among the public and the medical community.

Chapter 4 Analysis of the Reasons for ST Jiyao's Difficulties

4.1 Analysis of the Industry Environment

The pharmaceutical industry in China has been facing challenges in recent years. The government has been promoting the reform of the medical and healthcare system, which has led to changes in the pricing and reimbursement policies of drugs. The government has also been encouraging the development of innovative drugs and the elimination of low-quality and low-price drugs. These policies have increased the competition in the pharmaceutical industry and have put pressure on the profitability of pharmaceutical companies.

In addition, the outbreak of the COVID-19 pandemic has also had an impact on the pharmaceutical industry. Although the demand for drugs has increased, the pandemic has disrupted the supply chain and the production process of pharmaceutical companies. The pandemic has also caused delays in the approval process of new drugs, which has affected the research and development of pharmaceutical companies.

4.2 Analysis of ST Jiyao's Internal Issues

ST Jiyao's difficulties are not only caused by the external environment but also by its internal issues. The following are the main internal issues of ST Jiyao:

(1) The lack of innovation: ST Jiyao's research and development of new drugs have been lagging behind other pharmaceutical companies. The company's investment in research and development is relatively low, and its product pipeline is relatively weak. The lack of innovation has affected the company's competitiveness and its ability to adapt to changes in the industry.

(2) The lack of brand influence: ST Jiyao's brand influence is relatively weak compared to other pharmaceutical companies. The company's marketing and promotion efforts are relatively low, and its brand image is not well established. The lack of brand influence has affected the company's ability to attract customers and expand its market share.

(3) The lack of quality control: ST Jiyao's quality control system has been criticized by the regulatory authorities. The company's production process and quality management system have been found to be inadequate, which has led to the suspension of production and the recall of products. The lack of quality control has affected the company's reputation and its ability to ensure the safety and efficacy of its products.

Chapter 5 Suggestions for ST Jiyao's Future Development

5.1 Strengthening Innovation

ST Jiyao should increase its investment in research and development and strengthen its innovation capabilities. The company should focus on the development of innovative drugs, such as biologics and targeted therapies. The company should also establish partnerships with research institutions and universities to enhance its research and development capabilities.

5.2 Enhancing Brand Influence

ST Jiyao should enhance its brand influence and improve its marketing and promotion efforts. The company should establish a clear brand positioning and develop a comprehensive marketing plan. The company should also improve its customer service and establish a good reputation in the industry.

5.3 Improving Quality Control

ST Jiyao should improve its quality control system and ensure the safety and efficacy of its products. The company should establish a strict quality management system and improve its production process. The company should also strengthen its quality inspection and testing capabilities to ensure the quality of its products.

5.4 Reducing Debt Ratio

ST Jiyao should reduce its debt ratio and improve its financial performance. The company should optimize its capital structure and reduce its reliance on debt financing. The company should also improve its profitability and generate more cash flow to repay its debts.

Conclusion

ST Jiyao Co., Ltd. is facing a series of challenges, such as declining profits, increasing debts, and regulatory issues. These problems are caused by both the external environment and the company's internal issues. ST Jiyao should strengthen its innovation, enhance its brand influence, improve its quality control, and reduce its debt ratio to ensure its future development. By doing so, ST Jiyao can overcome its difficulties and achieve sustainable growth in the pharmaceutical industry.